Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines

 Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers
                      Squibb for RNA-targeted medicines

  PR Newswire

  HOERSHOLM, Denmark, and SAN DIEGO, April 16, 2013

HOERSHOLM, Denmark, and SAN DIEGO, April 16, 2013 /PRNewswire/ -- Santaris
Pharma A/S, a privately held biopharmaceutical company focused on developing
medicines targeted to disease-related mRNAs and microRNAs, today announced a
worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to discover
and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic
Acid (LNA) Drug Platform.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO )

Under the terms of the agreement, Santaris Pharma will receive an upfront
payment of $10 million, up to $90 million in potential milestone payments per
product and funding of ongoing discovery and research activities. In addition,
Santaris Pharma will be eligible to receive royalties on the worldwide sales
of all medicines arising from the alliance.

Announcing the alliance, President and CEO of Santaris Pharma, Henrik Stage,
said: "We are delighted to welcome Bristol-Myers Squibb as a new partner. This
strategic alliance further consolidates Santaris Pharma's leadership in the
field of oligonucleotide therapeutics."

Dr Henrik Oerum, Santaris Pharma's Chief Scientific Officer and VP Business
Development commented: "We are proud and honored that Bristol-Myers Squibb has
chosen Santaris Pharma as their partner. We are confident that the unique
features of the LNA Drug platform can achieve clinical breakthroughs and look
forward to working closely with the Bristol-Myers Squibb team."

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma
A/S combines the company's proprietary LNA chemistry with its highly
specialized and targeted drug development capabilities to rapidly deliver
LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a
range of diseases including infectious and inflammatory diseases,
cardiometabolic disorders, cancer and rare genetic disorders. LNA-based drugs
are a promising new class of therapeutics that are enabling scientists to
develop drug candidates that target previously inaccessible clinical pathways.
The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA
technologies to deliver potent single-stranded LNA-based drug candidates
across a multitude of disease states. The unique combination of small size and
very high affinity allows this new class of drug candidates to potently and
specifically inhibit RNA targets in many different tissues without the need
for complex delivery vehicles. The most important features of LNA-based drugs
include excellent specificity providing optimal targeting; increased affinity
to targets providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical
company focused on the discovery and development of RNA-targeted therapies.
The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma
A/S combine the company's proprietary LNA chemistry with its highly
specialized and targeted drug development capabilities to rapidly deliver
potent single-stranded LNA-based drug candidates across a multitude of disease
states. The company's research and development activities focus on infectious
diseases and cardiometabolic disorders, while partnerships with major
pharmaceutical companies include a range of therapeutic areas including
cancer, cardiovascular disease, infectious and inflammatory diseases, and rare
genetic disorders. The company has strategic partnerships with miRagen
Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals.
As part of its broad patent estate, the company holds exclusive worldwide
rights to manufacture, have manufactured and sell products that contain LNA as
an active ingredient for studies performed with a view to obtaining marketing
approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark
with operations in the United States. Please visit www.santaris.com for more
information.

Santaris Pharma Forward-Looking Statements

This written announcement contains forward-looking statements, identified by
the use of words such as "believes," "expects," "may," "will," "should",
"potential," "anticipates," "plans" or "intends" and similar expressions. Such
forward-looking statements involve risks, uncertainties and other factors that
may cause actual results, events or developments to be materially different
from the future results, events or developments indicated in this
announcement. Such factors include, but are not limited to the timing, success
and cost of clinical studies; the ability to obtain regulatory approval of
products, market acceptance of and future demand for Santaris Pharma products
and the impact of competitive products and pricing. These factors should be
considered carefully and readers are cautioned not to place undue reliance on
such forward-looking statements. No assurance can be given that the future
results covered by the forward-looking statements will be achieved. All
information in this press release is as of the date of this press release and
Santaris Pharma does not intend to update this information.

Website: http://www.santaris.com
Contact: Henrik Stage, President & CEO, Cell, (+45) 4026 0900,
hs@santaris.com; or Henrik Oerum, CSO & VP Business Development, Cell, +45
2834 6474, hoe@santaris.com